Cargando…
Future therapies for pancreatic carcinoma: Insights into cancer precision medicine
Pancreatic carcinoma (PC) has one of the highest rates of cancer-related death worldwide. Except for surgery, adjuvant chemotherapy, chemoradiotherapy, and immunotherapy have shown various efficacies depending on the stage of the patient. We read the review “Current and emerging therapeutic strategi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258281/ https://www.ncbi.nlm.nih.gov/pubmed/35979258 http://dx.doi.org/10.3748/wjg.v28.i22.2523 |
_version_ | 1784741514949165056 |
---|---|
author | Jiang, Qiu-Yu Chen, Zhi-Xue Zhang, Si Xue, Ru-Yi |
author_facet | Jiang, Qiu-Yu Chen, Zhi-Xue Zhang, Si Xue, Ru-Yi |
author_sort | Jiang, Qiu-Yu |
collection | PubMed |
description | Pancreatic carcinoma (PC) has one of the highest rates of cancer-related death worldwide. Except for surgery, adjuvant chemotherapy, chemoradiotherapy, and immunotherapy have shown various efficacies depending on the stage of the patient. We read the review “Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities” and offer some opinions that may improve its precision and completeness. This review presents a map of appropriate therapies for PC at different stages. Based on the clinical trial outcomes mentioned in the review, we evaluated the potential therapeutic options for PC and helped explain the contradictory efficacy between different programmed cell death protein 1/programmed cell death ligand 1 clinical trials, which may have resulted from the unique features of PC. Although R0 resection and adjuvant chemotherapy are still the gold standards for PC, new modalities, with or without clinical validation, are needed to establish more specific and precise treatments for PC. |
format | Online Article Text |
id | pubmed-9258281 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-92582812022-08-16 Future therapies for pancreatic carcinoma: Insights into cancer precision medicine Jiang, Qiu-Yu Chen, Zhi-Xue Zhang, Si Xue, Ru-Yi World J Gastroenterol Letter to the Editor Pancreatic carcinoma (PC) has one of the highest rates of cancer-related death worldwide. Except for surgery, adjuvant chemotherapy, chemoradiotherapy, and immunotherapy have shown various efficacies depending on the stage of the patient. We read the review “Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities” and offer some opinions that may improve its precision and completeness. This review presents a map of appropriate therapies for PC at different stages. Based on the clinical trial outcomes mentioned in the review, we evaluated the potential therapeutic options for PC and helped explain the contradictory efficacy between different programmed cell death protein 1/programmed cell death ligand 1 clinical trials, which may have resulted from the unique features of PC. Although R0 resection and adjuvant chemotherapy are still the gold standards for PC, new modalities, with or without clinical validation, are needed to establish more specific and precise treatments for PC. Baishideng Publishing Group Inc 2022-06-14 2022-06-14 /pmc/articles/PMC9258281/ /pubmed/35979258 http://dx.doi.org/10.3748/wjg.v28.i22.2523 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Letter to the Editor Jiang, Qiu-Yu Chen, Zhi-Xue Zhang, Si Xue, Ru-Yi Future therapies for pancreatic carcinoma: Insights into cancer precision medicine |
title | Future therapies for pancreatic carcinoma: Insights into cancer precision medicine |
title_full | Future therapies for pancreatic carcinoma: Insights into cancer precision medicine |
title_fullStr | Future therapies for pancreatic carcinoma: Insights into cancer precision medicine |
title_full_unstemmed | Future therapies for pancreatic carcinoma: Insights into cancer precision medicine |
title_short | Future therapies for pancreatic carcinoma: Insights into cancer precision medicine |
title_sort | future therapies for pancreatic carcinoma: insights into cancer precision medicine |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258281/ https://www.ncbi.nlm.nih.gov/pubmed/35979258 http://dx.doi.org/10.3748/wjg.v28.i22.2523 |
work_keys_str_mv | AT jiangqiuyu futuretherapiesforpancreaticcarcinomainsightsintocancerprecisionmedicine AT chenzhixue futuretherapiesforpancreaticcarcinomainsightsintocancerprecisionmedicine AT zhangsi futuretherapiesforpancreaticcarcinomainsightsintocancerprecisionmedicine AT xueruyi futuretherapiesforpancreaticcarcinomainsightsintocancerprecisionmedicine |